Novel sulindac derivatives for colorectal cancer chemoprevention that target cGMP phosphodiesterases to suppress Wnt/β-catenin transcriptional activity is a research paper published in Cancer Insight (2023). On theSindex it has a DataRank of 0. It has been cited 2 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 5R01CA238514-02
Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatment
National Institutes of Health
Grant: 5R01CA155638-04
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer Chemopreventi
National Institutes of Health
Grant: 3R01CA131378-08S1
Selective anti-cancer activity of sulindac derivatives on KRAS mutant colon tumor cells by inducing ROS
National Institutes of Health
Grant: 5R01CA254197-03
Novel inhibitor for oncogenic RAS for lung cancer
National Institutes of Health
Grant: 5R01CA197147-05
Phosphodiesterase 10A, a novel target for lung cancer chemoprevention
FWCI
0.43
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals